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aBstraCt
This is a case report of a patient diagnosed with Eales’ disease. Characteristics, etiology and symptoms will be descri-
bed in this study. Moreover, we will present case of a 61-year-old woman and discuss the clinical features, treatment 
plan and its outcome in our patient.
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introduCtion
Eales’ disease was first described by the Brit-
ish ophthalmologist in 1880 by Henry Eales, who 
thought that it is a non-inflammatory condition. 
The definition and etiology of Eales’ disease are not 
adequately established [1]. In recent years, clinical 
and basic research, have provided significant clues 
to the understanding of the clinical features and 
etiology of Eales’ disease [2]. It is an idiopathic pe-
ripheral retinal vasculopathy characterized by three 
overlapping stages of venus inflammation (vasculi-
tis), occlusion and retinal features [2]. Other fea-
tures of the disease are phlebitis, dilated aneurismal 
changes, shunt vessels and even macular edema [3]. 
Patients may present with decreased vision, photop-
sia and floaters unilaterally or bilaterally. Its etiol-
ogy appears to be multifactorial [5]. It is claimed 
that hypertensive patients are prone to have this 
disease. The management depends on the stage of 
the disease and consists of medical treatment with 
oral corticosteroids in the active inflammatory stage 
and laser photocoagulation in the advanced retinal 
ischemia and neovascularization stages [5]. 
Case report 
A 61-year-old woman complaining about float-
ers. Floaters caused by the mild vitreous haemor-
rhage. Her best corrected visual acuity (BCVA) was 
20/20 in both eyes. The image we got through the 
OCT (Spectralis HRA+OCT, Heidelberg Engineer-
ing, Germany), revealed a preretinal haemorrhage 
in her left eye at her lower vascular arcade (Fig. 1).
The patient informed about her personal case 
history with hypertension and hereditary glaucoma 
coming from her father’s side. Dr. Mallias decided 
that a multicolor imaging and a fluorescein angiog-
raphy were essential in order to fully diagnose the 
case (Fig. 2). 
The fluorescein angiography demonstrated ab-
normal staining in areas of vascular sheathing [6]. 
At the early stage of the examination, an area of 
hypo-fluorescence at the lower vascular arcade was 
found, which was attributed (Fig. 3) to a prereti-
nal haemorrhage. Moreover, supertemporal to the 
macula an area of extended retinal ischemia was ob-
Figure 1. Left eye macula’s image through the OCT imaging
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served, as well as the existence of multiple collateral 
vessels, in which small areas of focal hyper-fluores-
cence were found, being attributed to minor aneu-
risms. At the late stage of the examination, leak-
age of the fluorescence dye substance was observed 
which was attributed  to retinal neovascularization. 
In addition, there was a leakage of the dye substance 
through the inner side of the veins of the retina. We 
performed a tuberculin test which turned out to 
be negative.
Argon laser photocoagulation was performed 
solely on the ischemic part of the retina. Three 
months later, we proceeded to a new fluorescein 
angiography where we observed that there was no 
retinal neovascularization. Furthermore, we noticed 
an improvement in the condition of the vessels and 
no vitreous haemorrhage occurred ever since.
disCussion
The findings are compatible with Eales’ dis-
ease, which is found at the late stage of retinal 
Figure 2. Left eye’s image through the multicolor imaging
Figure 3. Left eye’s image through the fluorescein angiography
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ischemia accompanied by retinal neovasculari-
zation. The application of Argon Laser photo-
coagulation solely on the affected by ischemia 
area of the retina is recommended. With vascular 
non-perfusion and retinal neovascularization, in-
travitreal anti-VEGF therapy may be successful, 
however, its effects may cause vitreoretinal con-
traction [7]. In patients with exposure to tu-
berculosis, anti-tubercular therapy can be given 
for 9 months, but this is reserved for patients 
with massive infiltration, nodule formation, and 
venous obliteration. For non-resolving vitreous 
haemorrhage and/or retinal detachment (whether 
tractional, rhegmatogenous or combined), pars 
plana vitrectomy is necessary, with or without 
other vitreoretinal surgical procedures [8]. En-
dolaser treatment may be applied at the time of 
surgery. Vitrectomy for non-resolving vitreous 
haemorrhage should be performed no later than 
6 months following onset of haemorrhage [9].
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